Shares of Puma Biotechnology plunge after the company reveals that more patients than expected have discontinued treatment with its breast cancer drug, Nerlynx, prompting several analyst downgrades.
Novartis gets a potentially blockbuster eye drug and Takeda gets to unload some debt and employees it took on when it purchased Shire.
I am incrementally using buy-write option orders to add some shares to core holdings.
Regeneron Pharmaceuticals revenue expected to rise 16.8% to $1.8 billion.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.